Available markers in the diagnosis and prognosis of kidney cancer
Keywordsrenal cell carcinoma, targeted treatment, molecular markers
Introduction and purpose:
Renal cell carcinoma (RCC) is the most common kidney cancer that has no symptoms for a long time. It is most often diagnosed accidentally during abdominal ultrasound or abdominal computed tomography, performed primarily due to non-specific clinical symptoms. Despite progress in treatment, late detection is associated with poor prognosis. The aim of the study is to analyze literature (database PubMed) for potential prognostic markers and those used in RCC diagnostics.
A brief description of the state of knowledge:
The most common RCC subtype is clear cell renal cell carcinoma(ccRCC). Metastatic ccRCC is associated with poor prognosis. The pathogenesis of ccRCC includes, among others, disorders of miRNA change. These molecules are described as a promising marker of both diagnostic and prognostic. Detection of CD163 + antigen on cancer cells may be useful in assessing the clinical course of ccRCC patients. In clinical diagnosis of RCC, the presence of mutations and epigenetic inactivation of the von Hippel-Lindau (VHL) gene, vascular endothelial growth factor (VEGF) and carbonic anhydrase IX (CIAX) genes are particularly important. Plasma CIAX levels are described as not only a diagnostic and prognostic marker, but also lymph node involvement. There are studies on molecular markers that can also be a therapeutic target, including Caveolin-1 (CAV1), CCL5. Recent research results show a link between PDL1 expression and high-grade tumors. PDL-1 may also be an important prognostic factor.
Research on molecular markers is a promising personalized diagnostic and prognostic route. The limitation is the nonspecificity of molecular markers, so research on new and current markers is needed.
Turajlic S., Swanton C., Boshoff C.; Kidney cancer: The next decade.;J Exp Med. 2018 Oct 1;215(10):2477-2479. doi: 10.1084/jem.20181617. Epub 2018 Sep 14.
Gray RE, Harris GT.;Renal Cell Carcinoma: Diagnosis and Management;Am Fam Physician. 2019 Feb 1;99(3):179-184. Review. Erratum in: Am Fam Physician. 2019 Jun 15;99(12):732.
Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7:245–257. 10.1038/nrurol.2010.46
Wang G, Hou J, Ma L, Xie J, Yin J, Xu D, et al. Risk factor for clear cell renal cell carcinoma in Chinese population: a case-control study. Cancer Epidemiol. 2012;36:177–182. 10.1016/j.canep.2011.09.006.
Long JA, Descotes JL, Rambeaud JJ.;Kidney cancer diagnosis;Rev Prat. 2007 Mar 31;57(6):603-12.
Inamura K.; Renal Cell Tumors: Understanding Their Molecular Pathological Epidemiology and the 2016 WHO Classification.; Int J Mol Sci. 2017 Oct 20;18(10). pii: E2195.
The Cancer Genome Atlas Research Network Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43–49.
Kumar A, Kumari N, Gupta V i in.; Renal cell carcinoma: molecular aspects; Indian J Clin Biochem 2018; 33 : 246–54.
Goebell PJ, Staehler M, Müller L, Nusch A, Scheffler M, Sauer A et. al; Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma - Analyses From the German Clinical RCC-Registry; Clin Genitourin Cancer. 2018 Dec;16(6):e1101-e1115.
Zhou L, Pan X, Li Z, Chen P, Quan J, Lin C et. al.; ;Oncogenic miR-663a is associated with cellular function and poor prognosis in renal cell carcinoma;Biomed Pharmacother. 2018 Sep;105:1155-1163.
Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M et al.;Renal cell carcinoma; Nat Rev Dis Primers. 2017 Mar 9;3:17009.
Hsieh JJ, Le VH, Oyama T, Ricketts CJ, Ho TH, Cheng EH.;Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma; J Clin Oncol. 2018 Oct 29:JCO2018792549.
Lucarini L, Magnelli L, Schiavone N, Crisci A, Innocenti A, Puccetti L et al.; Plasmatic carbonic anhydrase IX as a diagnostic marker for clear cell renal cell carcinoma; J Enzyme Inhib Med Chem. 2018 Dec;33(1):234-240.
Young JR, Coy H, Kim HJ, Douek M, Sisk A, Pantuck AJ et al.; Association of the Gross Appearance of Intratumoral Vascularity at MDCT With the Carbonic Anhydrase IX Score in Clear Cell Renal Cell Carcinoma; AJR Am J Roentgenol. 2018 Dec;211(6):1254-1258.
Samberkar S, Rajandram R, Mun KS, Samberkar P, Danaee M, Zulkafli IS.;Carbonic anhydrase IX immunohistochemistry has potential to predict renal cell carcinoma outcomes: A systematic review and meta-analyses;Malays J Pathol. 2019 Dec;41(3):233-242.
Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M et al..;Renal cell carcinoma;Nat Rev Dis Primers. 2017 Mar 9;3:17009.
Ma C, Horlad H, Ohnishi K, Nakagawa T, Yamada S, Kitada S, Motoshima T et al.; CD163-positive cancer cells are potentially associated with high malignant potential in clear cell renal cell carcinoma;Med Mol Morphol. 2018 Mar;51(1):13-20
Martínez-Sáez O, Gajate Borau P, Alonso-Gordoa T, Molina-Cerrillo J, Grande E.;Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy; Crit Rev Oncol Hematol. 2017 Mar;111:117-123.
Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F et al.;Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016 Nov 3;539(7627):112-117.
Nogueira I, Dias F, Teixeira AL, Medeiros R.;miRNAs as potential regulators of mTOR pathway in renal cell carcinoma; Pharmacogenomics. 2018 Feb;19(3):249-261.
Ruan H, Li X, Yang H, Song Z, Tong J, Cao Q et al.; Enhanced expression of caveolin-1 possesses diagnostic and prognostic value and promotes cell migration, invasion and sunitinib resistance in the clear cell renal cell carcinoma; Exp Cell Res. 2017 Sep 15;358(2):269-278.
Lin J, Yu M, Xu X, Wang Y, Xing H, An J et. al.; Identification of biomarkers related to CD8+ T cell infiltration with gene co-expression network in clear cell renal cell carcinoma; Aging (Albany NY). 2020 Feb 20;12(4):3694-3712.
Chandrasekaran D, Sundaram S, N K, R P.;Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma; Asian Pac J Cancer Prev. 2019 Oct 1;20(10):2951-2957.
Kelsey R.;Kidney cancer: PDL1 as a biomarker in high-risk RCC; Nat Rev Urol. 2018 Apr;15(4):202.
Osmán-García I, Congregado-Ruiz CB, Lendínez-Cano G, Baena-Villamarin C, Conde-Sanchez JM, Medina-López RA.; Outcomes and Safety of Biweekly and Monthly Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Dialysis: Three Case Reports and Literature Review; Urol Int. 2020 Jan 8:1-4.
Posadas EM, Limvorasak S, Figlin RA.;Targeted therapies for renal cell carcinoma; Nat Rev Nephrol. 2017 Aug;13(8):496-511.
Yuan ZX, Fang P, Zhou L, Lim LY, Fu H, Lin J.;Targeting Strategies for Renal Cancer Stem Cell Therapy;Curr Pharm Des. 2020 Mar 18.
How to Cite
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Number of views and downloads: 210
Number of citations: 0